You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
|
|---|---|
| Published in |
Journal of Hematology & Oncology, January 2017
|
| DOI | 10.1186/s13045-016-0380-0 |
| Pubmed ID | |
| Authors |
Kurt Schönfeld, Chantal Zuber, Jan Pinkas, Thomas Häder, Katrin Bernöster, Christoph Uherek |
| Abstract |
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 31% |
| Researcher | 7 | 27% |
| Student > Master | 4 | 15% |
| Student > Bachelor | 2 | 8% |
| Professor | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 2 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 27% |
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Agricultural and Biological Sciences | 3 | 12% |
| Immunology and Microbiology | 2 | 8% |
| Other | 4 | 15% |
| Unknown | 3 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2020.
All research outputs
#7,003,498
of 22,947,506 outputs
Outputs from Journal of Hematology & Oncology
#471
of 1,194 outputs
Outputs of similar age
#131,423
of 422,106 outputs
Outputs of similar age from Journal of Hematology & Oncology
#15
of 39 outputs
Altmetric has tracked 22,947,506 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,194 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,106 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.